Literature DB >> 29939968

Fecal microbial transplantation: an update.

Sonia Bouri1, Ailsa Hart.   

Abstract

PURPOSE OF REVIEW: The purpose of this article is to provide an update on recent developments in fecal microbiota transplantation (FMT) in the last year. RECENT
FINDINGS: Although FMT is an accepted treatment for recurrent Clostridium difficile infection (CDI), recently it is also gaining acceptance for the treatment of refractory CDI. FMT is showing promise in ulcerative colitis and is experimental in many other conditions. The optimal practical aspects to enhance the success of FMT are still being established.
SUMMARY: The implication of current research is that the indications of FMT may be extended to other conditions in the future.

Entities:  

Mesh:

Year:  2018        PMID: 29939968     DOI: 10.1097/MCO.0000000000000488

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  4 in total

1.  Fecal transplantation alleviates acute liver injury in mice through regulating Treg/Th17 cytokines balance.

Authors:  Yongmei Liu; Linda Fan; Zhuo Cheng; Lei Yu; Shuo Cong; Yaxin Hu; Lili Zhu; Baofang Zhang; Yiju Cheng; Peiling Zhao; Xueke Zhao; Mingliang Cheng
Journal:  Sci Rep       Date:  2021-01-15       Impact factor: 4.379

Review 2.  Gut Microbiota in NSAID Enteropathy: New Insights From Inside.

Authors:  Xianglu Wang; Qiang Tang; Huiqin Hou; Wanru Zhang; Mengfan Li; Danfeng Chen; Yu Gu; Bangmao Wang; Jingli Hou; Yangping Liu; Hailong Cao
Journal:  Front Cell Infect Microbiol       Date:  2021-07-06       Impact factor: 5.293

3.  Fecal microbiota transplantation for patients with irritable bowel syndrome: A meta-analysis protocol.

Authors:  Wenting Wen; Haibo Zhang; Junlong Shen; Luxia Wei; Shunong Shen
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

Review 4.  The microbiota-gut-brain axis: A promising avenue to foster healthy developmental outcomes.

Authors:  Bonnie E Brett; Carolina de Weerth
Journal:  Dev Psychobiol       Date:  2019-01-14       Impact factor: 3.038

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.